SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-134596
Filing Date
2022-05-02
Accepted
2022-04-29 19:22:15
Documents
13
Period of Report
2022-04-28
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d193117d8k.htm   iXBRL 8-K 42947
2 EX-99.1 d193117dex991.htm EX-99.1 358096
  Complete submission text file 0001193125-22-134596.txt   620853

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA hznp-20220428.xsd EX-101.SCH 2875
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE hznp-20220428_lab.xml EX-101.LAB 17168
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE hznp-20220428_pre.xml EX-101.PRE 10801
7 EXTRACTED XBRL INSTANCE DOCUMENT d193117d8k_htm.xml XML 3353
Mailing Address CONNAUGHT HOUSE, 1ST FLOOR 1 BURLINGTON ROAD DUBLIN L2 4
Business Address CONNAUGHT HOUSE, 1ST FLOOR 1 BURLINGTON ROAD DUBLIN L2 4 011-353-1-772-2100
Horizon Therapeutics Public Ltd Co (Filer) CIK: 0001492426 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35238 | Film No.: 22878500
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences